Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis

This publication has 27 references indexed in Scilit:

• Vaccination withLeishmaniasoluble antigen and immunostimulatory oligodeoxynucleotides induces specific immunity and protection againstLeishmania donovaniinfection
  FEMS Immunology & Medical Microbiology, 2004
• Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (S o Gon alo do Amarante, RN)
  Vaccine, 2002
• Vaccination with Heat-killed Leishmania Antigen or Recombinant Leishmanial Protein and CpG Oligodeoxynucleotides Induces Long-Term Memory CD4+and CD8+T Cell Responses and Protection Against Leishmania major Infection
  The Journal of Experimental Medicine, 2002
• Recombinant cysteine proteinases-based vaccines against Leishmania major in BALB/c mice: the partial protection relies on interferon gamma producing CD8+ T lymphocyte activation
  Vaccine, 2002
• Leishmania donovanip36(LACK) DNA Vaccine Is Highly Immunogenic but Not Protective against Experimental Visceral Leishmaniasis
  Infection and Immunity, 2001
• A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major
  Vaccine, 2001
• A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (S o Gon alo do Amaranto, RN)
  Vaccine, 2000
• BCG Expressing LCR1 of Leishmania chagasi Induces Protective Immunity in Susceptible Mice
  Experimental Parasitology, 2000
• The Epidemic of Visceral Leishmaniasis in Western Upper Nile, Southern Sudan: Course and Impact from 1984 to 1994
  International Journal of Epidemiology, 1996
• Imidazole‐SDS‐Zn reverse staining of proteins in gels containing or not SDS and microsequence of individual unmodified electroblotted proteins
  FEBS Letters, 1992